Article thumbnail

Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

By Weerawat Manosuthi, Preecha Tantanathip, Wisit Prasithisirikul, Sirirat Likanonsakul and Somnuek Sungkanuparph
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2577100
Provided by: PubMed Central

Suggested articles

Citations

  1. (2004). Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramunezyrtec double-blind, placebo-controlled trial. Clin Infect Dis
  2. (2006). Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. Aids
  3. (2003). Casas E, Marino A: Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. Aids
  4. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med
  5. (1999). de Ruiter A: Effect of tuberculosis therapy on nevirapine trough plasma concentrations. Aids
  6. (2008). Delaporte E: Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens
  7. (2008). Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. Aids
  8. (2008). et al.: Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIVinfected patients.
  9. (2008). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults
  10. (2004). Lonergan JT: Mitochondrial dysfunction: patient monitoring and toxicity management.
  11. (2008). Maartens G: Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
  12. (2005). Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther
  13. (2001). Pahissa A: Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr
  14. (2006). Raffi F: Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med
  15. (2006). Ruxrungtham K: Plasma nevirapine levels and 24-week efficacy in HIVinfected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis
  16. (2006). Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a public Health Approach. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO).
  17. (2007). Sungkanuparph S: Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis
  18. (2008). Sungkanuparph S: Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med
  19. (2006). Sungkanuparph S: Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr
  20. (2007). Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. Aids
  21. (2007). Zijlstra EE: Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.